Eurosurv. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine ad

[tetano]

• Alberto Mateo-Urdiales[SUP]1,2[/SUP] , Stefania Spila Alegiani[SUP]3[/SUP] , Massimo Fabiani[SUP]1[/SUP] , Patrizio Pezzotti[SUP]1[/SUP] , Antonietta Filia[SUP]1[/SUP] , Marco Massari[SUP]3[/SUP] , Flavia Riccardo[SUP]1[/SUP] , Marco Tallon[SUP]4[/SUP] , Valeria Proietti[SUP]5[/SUP] , Martina Del Manso[SUP]1,2[/SUP] , Maria Puopolo[SUP]6[/SUP] , Matteo Spuri[SUP]1[/SUP] , Cristina Morciano[SUP]7[/SUP] , Fortunato (Paolo) D’Ancona[SUP]1[/SUP] , Roberto Da Cas[SUP]3[/SUP] , Serena Battilomo[SUP]5[/SUP] , Antonino Bella[SUP]1[/SUP] , Francesca Menniti-Ippolito[SUP]3[/SUP] , on behalf of the Italian Integrated Surveillance of COVID-19 study group[SUP]8[/SUP] , on behalf of the Italian COVID-19 vaccines registry[SUP]9[/SUP]

To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0–14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21–0.24) 43–49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09–0.15) and 93% (IRR: 0.07; 95% CI: 0.04–0.11) reductions 36–42 days post-first dose. Our results support ongoing vaccination campaigns.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.25.2100507#html_fulltext